{
  "slug": "alnylam-pharmaceuticals",
  "name": "Alnylam Pharmaceuticals",
  "description": "Alnylam Pharmaceuticals is a biopharmaceutical company that pioneers RNA interference (RNAi) therapeutics. Their innovative medicines work by silencing the genes that cause or contribute to disease, aiming to amplify life for patients with rare and prevalent diseases.",
  "url": "https://optimly.ai/brand/alnylam-pharmaceuticals",
  "websiteUrl": null,
  "logoUrl": "https://logo.clearbit.com/https://www.alnylam.com/",
  "baiScore": 50,
  "bai_tier_status": "active",
  "bai_score_status": "active",
  "archetype": "Incumbent",
  "archetype_status": "active",
  "category": "Biotechnology",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "competitorsProse": null,
  "inboundCompetitors": [],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-07-15T01:28:22.329Z",
  "verifiedVitals": {
    "website": "https://www.alnylam.com/",
    "founded": "2002",
    "headquarters": "Cambridge, MA",
    "pricing_model": "Not specified in the provided text, but typical for biopharmaceutical companies, often involving complex reimbursement models.",
    "core_products": "RNAi therapeutics designed to silence genes responsible for various diseases, including hATTR Amyloidosis, Acute Intermittent Porphyria, and Primary Hyperoxaluria Type 1.",
    "key_differentiator": "Pioneering and leading expertise in RNA interference (RNAi) therapeutics, offering a unique approach to treat diseases by addressing their genetic origin at the source.",
    "target_markets": "Patients suffering from rare and prevalent genetic diseases globally.",
    "employee_count": "Not specified in the provided text.",
    "funding_stage": "Publicly Traded (NASDAQ: ALNY)",
    "subcategory": "RNAi Therapeutics"
  },
  "intentTags": {
    "problemIntents": [
      "Gene Therapy or Gene Editing Approaches: For some genetic diseases, alternatives like gene therapy (e.g., AAV-based therapies) or gene editing (e.g., CRISPR) could be considered, though these represen",
      "Symptomatic Treatment or Palliative Care: For many rare and severe genetic diseases, especially without targeted therapies like RNAi, patients might only have access to treatments that manage symptoms"
    ],
    "solutionIntents": [
      "Alnylam Pharmaceuticals",
      "RNAi therapeutics company",
      "Alnylam rare diseases",
      "Silence disease amplify life",
      "Traditional Biologics or Small Molecule Drugs: Patients might rely on conventional pharmaceutical treatments, which may target symptoms or different pathways, rather than directly silencing the diseas"
    ],
    "evaluationIntents": []
  },
  "timestamp": 1784110932979
}